Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Dowsett

Showing results (161-170 of 304) with videos related to

Pageof 31
Sort By:
Cancer Research|January 15, 1995
Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancerA A Daffada, S R Johnston, I E Smith, et al.
The Journal of Steroid Biochemistry and Molecular Biology|September 1, 1994
Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase)S E Barrie, G A Potter, P M Goddard, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifenS R Johnston, K A MacLennan, N P Sacks, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 7, 2012
Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancerM T Weigel, S Banerjee, M Arnedos, et al.
British Journal of Cancer|October 1, 1992
The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancerF A MacNeill, A L Jones, S Jacobs, et al.
Cancer Research|January 15, 1993
Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancerT J Iveson, I E Smith, J Ahern, et al.
Cancer Research|November 1, 1991
Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancerS K Chander, R McCague, Y Luqmani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 25, 2006
Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 statusM Dowsett, J Houghton, C Iden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 1998
In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patientsJ Geisler, N King, G Anker, et al.
Steroids|April 12, 2011
An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibitionL-A Martin, Z Ghazoui, M T Weigel, et al.
Pageof 31

Showing results (161-170 of 304) with videos related to

Sort By:
Pageof 31
Cancer Research|January 15, 1995
Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancerA A Daffada, S R Johnston, I E Smith, et al.
The Journal of Steroid Biochemistry and Molecular Biology|September 1, 1994
Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase)S E Barrie, G A Potter, P M Goddard, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifenS R Johnston, K A MacLennan, N P Sacks, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 7, 2012
Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancerM T Weigel, S Banerjee, M Arnedos, et al.
British Journal of Cancer|October 1, 1992
The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancerF A MacNeill, A L Jones, S Jacobs, et al.
Cancer Research|January 15, 1993
Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancerT J Iveson, I E Smith, J Ahern, et al.
Cancer Research|November 1, 1991
Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancerS K Chander, R McCague, Y Luqmani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 25, 2006
Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 statusM Dowsett, J Houghton, C Iden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 1998
In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patientsJ Geisler, N King, G Anker, et al.
Steroids|April 12, 2011
An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibitionL-A Martin, Z Ghazoui, M T Weigel, et al.
Pageof 31